Why is Morepen Labs. falling/rising?

Recent Price Movement and Market Context

Morepen Laboratories closed at ₹39.75 on 17 December, down ₹1.15 or 2.81% from the previous close. The stock hit a new 52-week low of ₹39.41 during the day, marking a continuation of a three-day losing streak that has seen the share price decline by 4.29%. This recent weakness contrasts starkly with the broader market, as the Sensex gained 0.20% over the past week, underscoring Morepen Labs’ relative underperformance.

Over the past month, the stock has declined by 14.02%, significantly worse than the Sensex’s marginal fall of 0.46%. Year-to-date, Morepen Labs has lost 49.23% of its value, while the Sensex has risen by 8.22%. The one-year return is even more telling, with the stock down 53.40% compared to the Sensex’s 4.80% gain. This persistent underperformance highlights the challenges facing the company and investor sentiment.

Technical Indicators and Trading Activity

Technically, Morepen Labs is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a bearish trend. The weighted average price indicates that most trading volume occurred near the day’s low, suggesting selling pressure. Additionally, investor participation appears to be waning, with delivery volumes on 16 December falling by 7.59% compared to the five-day average. Despite this, liquidity remains adequate for modest trade sizes, with a 2% threshold of the five-day average traded value equating to approximately ₹0.09 crore.

Fundamental Weaknesses Weighing on the Stock

Morepen Laboratories’ financial performance has been underwhelming, contributing to the stock’s decline. The company has reported negative results for three consecutive quarters, with profit before tax excluding other income falling by 41.0% to ₹15.22 crore compared to the previous four-quarter average. Net profit after tax also declined by 23.7% to ₹17.67 crore in the same period. These results reflect operational challenges and pressure on profitability.

Long-term growth metrics are also subdued. Over the past five years, net sales have grown at an annual rate of 11.24%, while operating profit has increased by just 8.98% annually. Return on capital employed (ROCE) for the half-year period stands at a low 8.16%, indicating limited efficiency in generating returns from capital invested. Although the company maintains a low average debt-to-equity ratio of 0.01 times, its return on equity (ROE) of 6.3% suggests only modest profitability relative to shareholder equity.

Despite these challenges, the stock trades at a fair valuation with a price-to-book value of 1.8, which is in line with historical averages for its peer group. However, this valuation has not been sufficient to attract significant institutional interest. Domestic mutual funds hold no stake in Morepen Laboratories, which may reflect their cautious stance given the company’s recent performance and outlook.

Long-Term Underperformance and Investor Sentiment

Morepen Laboratories’ stock has consistently lagged broader market indices and sector benchmarks. Over the last three years, the stock has returned 25.79%, trailing the Sensex’s 37.86% gain. Its five-year return of 27.20% is also well below the Sensex’s 80.33% appreciation. This persistent underperformance has likely eroded investor confidence and contributed to the recent selling pressure.

The combination of weak quarterly earnings, lacklustre long-term growth, and absence of institutional backing has created a challenging environment for the stock. The recent decline to a new 52-week low and the failure to hold above key moving averages reinforce the bearish sentiment among market participants.

Conclusion

In summary, Morepen Laboratories’ share price decline on 17 December is a reflection of sustained financial underperformance, weak growth prospects, and a lack of institutional support. The stock’s failure to keep pace with market benchmarks and its recent technical breakdown have further dampened investor sentiment. While the company’s low debt and fair valuation offer some positives, these factors have not been sufficient to offset concerns over profitability and growth. Investors should remain cautious given the stock’s recent trend and fundamental challenges.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →